Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | NPC1 | O15118 | 1/20 | 0.30 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.30 |
| ▸ | RAB9A | P51151 | 1/20 | 0.30 |
| ▸ | TLR2 | O60603 | 1/20 | 0.30 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24344113 | 0.66 | KMT2A (0.41) | POLBHTTKMT2A | |
| SCHEMBL21013922 | 0.66 | NPC1 (0.30) | NPC1MAPTMAPK1RAB9A | |
| SCHEMBL3211286 | 0.66 | CHRNB2 (0.42) | POLBHTTKMT2ATLR2 | |
| SCHEMBL1563436 | 0.66 | CHRNB2 (0.42) | POLBHTTKMT2ATLR2 | |
| SCHEMBL19054663 | 0.66 | CHRNB2 (0.42) | POLBHTTKMT2ATLR2 | |
| Hydrochloric Acid SCHEMBL25329031 | 0.64 | CHRNB2 (0.41) | POLBHTTKMT2ATLR2 | |
| Hydrochloric Acid SCHEMBL25329033 | 0.64 | CHRNB2 (0.41) | POLBHTTKMT2ATLR2 | |
| SCHEMBL28898687 | 0.64 | HDAC8 (0.48) | POLBMAPK1RAB9A | |
| SCHEMBL16335635 | 0.63 | TLR2 (0.42) | POLBHTTNPC1RAB9ATLR2 | |
| SCHEMBL16335638 | 0.63 | TLR2 (0.42) | POLBHTTNPC1RAB9ATLR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10703748-B2 | Diazanaphthalen-3-yl carboxamides and preparation and use thereof | SAMUMED, LLC (US) | 2020-07-07 | — | — | US | disclosed |
| US-20190127370-A1 | DIAZANAPHTHALEN-3-YL CARBOXAMIDES AND PREPARATION AND USE THEREOF | VICKERS-SPLICE CO-INVESTMENT LLC (KY) | 2019-05-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190127370-A1 | DIAZANAPHTHALEN-3-YL CARBOXAMIDES AND PREPARATION AND USE THEREOF | DYRK1A, DKK1, WNT1 | POLB 3427/4885HTT 1428/4885KMT2A 1066/4885 |
| US-10703748-B2 | Diazanaphthalen-3-yl carboxamides and preparation and use thereof | DYRK1A, DKK1, WNT1 | POLB 3427/4885HTT 1428/4885KMT2A 1066/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.